Search research articles
Contact Us
Filters
Showing results (931-940 of 1,042) with videos related to
Page
of 105
Sort By:
Molecular Psychiatry
|
October 5, 2011
Promoter polymorphisms in two overlapping 6p25 genes implicate mitochondrial proteins in cognitive deficit in schizophrenia
A Jablensky, D Angelicheva, G J Donohoe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2015
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses
Miriam E Mossoba, David C Halverson, Roger Kurlander, et al.
Blood
|
September 24, 2013
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N Kochenderfer, Mark E Dudley, Robert O Carpenter, et al.
Cancer Research
|
May 14, 2025
SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer
Xianbing Zhu, Zheng Fu, Giulio Aceto, et al.
Transboundary and Emerging Diseases
|
June 22, 2010
Surveillance for African swine fever in Nigeria, 2006-2009
F O Fasina, D Shamaki, A A Makinde, et al.
NPJ Precision Oncology
|
September 17, 2022
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma
David S Shulman, Sarah B Whittle, Didier Surdez, et al.
Blood
|
April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Bijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
Leukemia
|
March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Journal for Immunotherapy of Cancer
|
December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V Maus, Sara Alexander, Michael R Bishop, et al.
Journal for Immunotherapy of Cancer
|
August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Page
of 105
Search research articles
Search
Showing results (931-940 of 1,042) with videos related to
Sort By:
Page
of 105
Molecular Psychiatry
|
October 5, 2011
Promoter polymorphisms in two overlapping 6p25 genes implicate mitochondrial proteins in cognitive deficit in schizophrenia
A Jablensky, D Angelicheva, G J Donohoe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2015
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses
Miriam E Mossoba, David C Halverson, Roger Kurlander, et al.
Blood
|
September 24, 2013
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N Kochenderfer, Mark E Dudley, Robert O Carpenter, et al.
Cancer Research
|
May 14, 2025
SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer
Xianbing Zhu, Zheng Fu, Giulio Aceto, et al.
Transboundary and Emerging Diseases
|
June 22, 2010
Surveillance for African swine fever in Nigeria, 2006-2009
F O Fasina, D Shamaki, A A Makinde, et al.
NPJ Precision Oncology
|
September 17, 2022
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma
David S Shulman, Sarah B Whittle, Didier Surdez, et al.
Blood
|
April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Bijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
Leukemia
|
March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Journal for Immunotherapy of Cancer
|
December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V Maus, Sara Alexander, Michael R Bishop, et al.
Journal for Immunotherapy of Cancer
|
August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Page
of 105